Form D · Pharmaceuticals
Relay Therapeutics, Inc.
Cambridge, MA · CIK 0001812364
Offering snapshot reported Jan 10, 2024 · SEC filing
- Reported sold
- $30M Offering amount: $30M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 10, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 10, 2024 | Initial | $30,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-502011
Source: Form D, filed Jan 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brian Adams | Executive |
| Donald A. Bergstrom | Executive |
| Alexis Borisy | Director |
| Thomas Catinazzo | Executive |
| Linda A. Hill | Director |
| Douglas S. Ingram | Director |
| Sekar Kathiresan | Director |
| Mark Murcko | Director |
| Sanjiv K. Patel | Director, Executive |
| Peter Rahmer | Executive |
| Jami Rubin | Director |
| Laura Shawver | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
399 Binney Street 2 Nd Floor
Cambridge, MA, 02139
Cambridge, MA, 02139